The world may be on the threshold of an era where pandemics become history. Scientists from the University of Cambridge, in collaboration with the company DIOSynVax, have presented a breakthrough technology — a universal vaccine capable of protecting humanity not only from known viruses but also from those that have not yet appeared in nature. The development is called Sarbeco.
How Artificial Intelligence Found the Weak Spot of Viruses
The key to success lies in changing the paradigm of vaccination. Instead of chasing a specific strain, researchers turned to artificial intelligence. Algorithms analyzed genetic data from thousands of different virus strains to find their common vulnerability.
Machine learning identified stable fragments — elements that practically do not change even during mutations. It is precisely these areas that the human immune system now targets. A technology called "superantigen" allows the formation of immunity against entire families of viruses with just one shot.
Results of the First Trials
The effectiveness of the new approach has already been tested in practice. In the first phase of clinical trials, held in Cambridge and Southampton, 49 healthy volunteers aged 18 to 50 participated. The results confirmed the complete safety of the Sarbeco drug.
The vaccine demonstrated the ability to work not only against SARS-CoV-2 but also to protect the body from bat viruses. This is a critically important step in preventing outbreaks of zoonotic infections that pass from animals to humans. Currently, researchers are preparing for the second phase of trials involving more than 200 people to finally confirm effectiveness.
No Syringes: New Delivery Technology
Innovations have affected not only the composition of the drug but also the method of its administration. Traditional syringes are becoming a thing of the past. The technology provides for the use of a microfluidic jet — a thin stream of liquid under ultra-high pressure. It penetrates directly into the skin cells in a fraction of a second, ensuring rapid delivery of the vaccine.
Why the Old System No Longer Works
Professor Sol Faust from the University of Southampton harshly criticizes the current model of fighting infections. According to him, the modern system is "reactive": vaccines are created post-factum, when the virus has already spread.
"Viruses such as influenza, coronaviruses, and the Ebola virus group are constantly evolving, and by the time vaccines are introduced, they may be poorly matched. The current system struggles to keep up with changes," notes Faust.
Professor Jonathan Gini from the Viral Zoonoses Laboratory added that the Covid-19 pandemic showed the speed of vaccine creation, but we are still using old logic. The new goal is to create a drug that will hit all viruses, depending on their genetic relationships.
Global Challenges and Prospects
The transition to preventive vaccination could save millions of lives and avoid destructive lockdowns. The world is currently in desperate need of such solutions. For example, the WHO calls the situation with the Ebola outbreak in Africa extremely alarming, and vaccines for this virus are still insufficient.
The problem of hantavirus is also relevant: a vaccine against it has been under development for years due to a lack of funding. A new class of universal vaccines, capable of outpacing virus evolution, could become the very tool that gives humanity an advantage in the fight against future threats.